4 news items
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
ABBV
6 Jun 24
/2 Steiner, T.J., Stovner, L.J., Jensen, R. et al. Migraine remains second among the world's causes of disability, and first among young
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
ABBV
31 May 24
to substantial burden and often disability among those living with the disease.6
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®
ABBV
17 May 24
in the colon (mucosal healing), a normal quality of life, and absence of disability.1
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
ABBV
12 Apr 24
States alone, and is the highest cause of disability worldwide for people under 50 years of age.2-5
- Prev
- 1
- Next